skip to main content

Opioid substitution supervised dose — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardCNS TherapeuticsOpioid substitution supervised doseGPhC CRA

A 38-year-old man collecting buprenorphine sublingual tablets for opioid dependence appears intoxicated and smells strongly of alcohol. His supervised dose is due now. He is drowsy but rousable and slurring speech. What is the most important interaction to flag?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — withhold the supervised dose and seek prescriber or key-worker advice because sedation increases overdose risk

Buprenorphine and alcohol both depress the central nervous system and can increase overdose risk. Supervised opioid substitution treatment should not be administered when the patient is significantly intoxicated or sedated without specialist advice. The pharmacist should follow the local SOP and contact the prescriber or drug service. Supplying the dose for later use would bypass supervision and create further risk.

Reference: BNF; MEP